Medicare Advantage plans are supporting efforts to halt inappropriate marketing tactics, partly to head off more stringent federal and state oversight designed to stop abusive practices. Last month, America’s Health Insurance Plans (AHIP) adopted a proposal urging enactment of new rules to prohibit certain marketing practices that violate Medicare policy.
Medicare Advantage plans are supporting efforts to halt inappropriate marketing tactics, partly to head off more stringent federal and state oversight designed to stop abusive practices. Last month, America’s Health Insurance Plans (AHIP) adopted a proposal urging enactment of new rules to prohibit certain marketing practices that violate Medicare policy.
The proposal would ban cold calling, door-to-door sales and cross selling of MA plans with other products. Insurers also backed a curb on inducements such as free meals or prizes to persuade seniors to sign up for private plans.
Senate Finance Committee chairman Max Baucus (D-Mont.) said he hoped to include these recommendations in broader Medicare legislation slated for action by summer. Leading Republicans on the House Ways & Means Committee urged Medicare officials to bolster regulation of MA marketing activities while Congress weighs the need for additional legislation.
Meanwhile, Sen. Herb Kohl (D-Wis.), chairman of the Senate Special Committee on Aging, backs a bill that would give states a larger role in enforcing action against illegal Medicare sales tactics and expressed skepticism that the latest industry proposal would go far enough to protect seniors. “We heard pledges and promises from this group before,” said Kohl, adding that it’s time to give states “more room to step up regulation and enforcement of the insurance industry.
Medicare Patients with PAH Face High Out-of-Pocket Costs | 2024 ATS
May 19th 2024Medicare patients who have pulmonary arterial hypertension and who are eligible for the low-income subsidy often have advanced disease, require prolonged disability insurance and face financial hardships, according to a poster at the annual ATS meeting.
Read More
FDA Updates for Week of May 13: First Bispecific Antibody for Solid Tumor
May 18th 2024The FDA has approved a new type of bispecific antibody to treat small cell lung cancer and an additional indication for Breyanzi for patients with follicular lymphoma. The agency has set review date for gene therapy for enzyme deficiency. In addition, Biogen have Eisai hve begun a rolling submission of subcutaneous Leqembi for Alzheimer’s disease.
Read More